{"name":"Servier Bio-Innovation LLC","slug":"servier-bio-innovation-llc","ticker":"","exchange":"","domain":"servierbioinnovationllc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ivosidenib Oral Tablet","genericName":"Ivosidenib Oral Tablet","slug":"ivosidenib-oral-tablet","indication":"Acute myeloid leukemia (AML) with IDH1 mutation","status":"phase_3"}]}],"pipeline":[{"name":"Ivosidenib Oral Tablet","genericName":"Ivosidenib Oral Tablet","slug":"ivosidenib-oral-tablet","phase":"phase_3","mechanism":"Ivosidenib is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that blocks the production of the oncometabolite 2-hydroxyglutarate, thereby promoting differentiation and apoptosis of IDH1-mutant cancer cells.","indications":["Acute myeloid leukemia (AML) with IDH1 mutation","Cholangiocarcinoma with IDH1 mutation","Other IDH1-mutant solid tumors (in development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxOLXZCV1UtMF93MHc2RTlXLWNVY1gzaW9oUjZZYjZEWWlNb1U2R1BFQUdqQ0YxTENzX3ZScTQ4a25fWC0zQWtnNlBiUnI2SkN4bzdJbk5hQmwtQWh6V3pKa3J5aFFMTXhWRWFCbjRvNG0tNnBwZWMxcDJhQjloR3F1RmM5Zk0yWjhqSmxuSWRDdWU2T3hVdmVRNlJGQkdiNnFmLU5pUWFGWTdzMlF6Q04yUzlYR3VxWVI5S1Y1dm9WOVl1Ull0d05xTTlLd3RhZmNlcXpBbERremFySEtTd0xTRW1wQ2hEbDRGNzJqdGZ4VjVvcHlQZUk1bmlaYjYxd2VlaUNITGJXV01zUERSZTBoV0o1ZUY?oc=5","date":"2026-03-09","type":"deal","source":"GlobeNewswire","summary":"kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics - GlobeNewswire","headline":"kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOTjRtTjZHMlloUTlfTjlIRnZaY085YnMyeGdMbV9kVk5RcDhOSUxXTlFyb2ZSTG52UU5YcHZObk5GRUtaeVFGamV5b1FiZi1hSjZBQjFud1pvajhHVmVqd0pEVF9ER0xJb2pfYzRacTlwSG9JVXFWNEtRWUdzb3R3MGp4MzBuNkFPVWQ0bmZB?oc=5","date":"2026-03-06","type":"pipeline","source":"Servier","summary":"Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio - Servier","headline":"Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOUG1IS1dlTU9RN0dKek5ydXRsT0FINjBNQlZLaHNjTmF1UXJVVVMyNXlGcVVCTnVMdElnUDA5XzVxZlB5QWhtb05tUHU1Vm1oVUt0dWdMUnpYM3F3TXlJZXJTNlZBeUhIWlpRVlZlRWVDNmtZaU96N1VWcTBVUVZZdzNTSXAzNVY0YlZSdExXYTNLWlVvZUJvX2dBQnk?oc=5","date":"2026-01-27","type":"earnings","source":"Fierce Pharma","summary":"Servier delivers 16% revenue jump, firming up €10B ambition by 2030 - Fierce Pharma","headline":"Servier delivers 16% revenue jump, firming up €10B ambition by 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZk9pbjdvVmM2Uy1kcm1FckRhMUd1YUJaVElUWHhfaEJ6NHJCTDBaWk42VllhWlV6dGJyd0FjZWVteERxOXNrOFVCTm9kRGc3eTVkbkpHb21jTDJWa051SG5PZU9EcFlmLUVzd0hCcURzLXREaEozWkJCQXduTnpfRjRpbUFzWjlk?oc=5","date":"2026-01-12","type":"pipeline","source":"Fierce Biotech","summary":"Servier Sharpens Its Focus on Rare Neurology - Fierce Biotech","headline":"Servier Sharpens Its Focus on Rare Neurology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQclU2QmVOVVZNcXUwQi1kbTExM1dFMnVwQWFrQ0t5eVh1VW81WEYyUVp3UHhBUTZoUWs3TEtqMUZFQkZzcWZhOHJ3ek1FZVBZV01jOGl0cnpvdlJ2bVd0Y3NWbVZtdFdGZVp2bFRvWWVBeWJQTVBmY2dBNjRhUGQ3bmwwWFppcFJJWDZoYVJiNlpvVlNSSDFoQ3lFbXFKS3QwRVE?oc=5","date":"2026-01-09","type":"deal","source":"Fierce Pharma","summary":"Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business - Fierce Pharma","headline":"Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPd1FqTkhLcU44U1pKUGxJZXVEWGoyT0g3QlZPaUF0c3lGNFJvbzZuME1Eb1FNVzAxU2d2QWljNUFWNi16U1RtUllGUHIzVXc4TVVQSTVfejZQN0QyQUdFaXZyRGJudHh1UF9xSUU5WTNqQWtCMW5nYV9rTFFON2Q0NWc3RmxTbF91YjFlOGlGQ01QWGx1VGwyS3NWVE1LenliNWhzTENOM1R5aWR5SFA2dGRoQQ?oc=5","date":"2026-01-04","type":"pipeline","source":"Fierce Biotech","summary":"Insilico, fresh off its Hong Kong IPO, pens potential $888M cancer R&D pact with Servier - Fierce Biotech","headline":"Insilico, fresh off its Hong Kong IPO, pens potential $888M cancer R&D pact with Servier","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQdGR1eDdsR2NuRThDRUIybjVZSXF1dmpLcUtpcDZoTUhJcTVPazVXZE4yZldBbmFFdnVKUDJkMEpHUFhQZUwwcFB1OV9tV0V0YjZPSVA1enpsZDVOYXFCU2xjVGpFZUhoYVJvVWJRbXFiRjhFQW1tbTVXbjJsQWxGdzJIajJuSXVGU25NeC0xZmFySkhFSlBCaWllbGJKeDFQS2U0bVNQMXVmZ3hBRmozZ3lR?oc=5","date":"2025-09-08","type":"deal","source":"Fierce Biotech","summary":"Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate - Fierce Biotech","headline":"Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxPV1lFZFBJRTc2UGhsallqajFaVTBycEhab1JxTWdkc1VmOGMycWJLdkstbXNTM0c0YWpxX0E1ajdxZDZCNEwtOXBpVVV5VVNqa2JybThTbTVSNmJ3blh5RkdPR0lOR2tyUXBTYVZaa1htQUhEbTNhbWFtcVBtNklVRldHYm9Odm5HaU5fNHhSS2JPbGc1ZEZIS3d1REpXNkNzRkd0TnBDak1LYUtTaWVWMVI1UUVZQ3BQazVFM1B1RGJsby10YUpfdlVxa1ZMc3hZVjNvUmg0NHgxLUZyeTJwODRyQ1hFeDJ4VllsWFhTOTBrOEhMZUtSVXBYamxRMkN0b3pqN05tNmFkbmQzeDNDNE9mTWtDaWN3Y0tnMnNnY1Q0SlM2aTBFY0ZVU1lwSFQ1SVQ2cE5ORXp1bnBwY0V2cw?oc=5","date":"2025-07-15","type":"regulatory","source":"PR Newswire","summary":"Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - PR Newswire","headline":"Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNTUQyMFhFTEFISmlZcFF0WXZvdHJBV1dKMWhXbENfb0hGSW9KLXhxZFlDLXhtT3NjSEJoVlI1aTQ4dUlVbURkbHRMb0pUbllhN3NzZ2VVRWNScWhJRXVvaURGVnFMTDBLMUNRNHdxOTZvNFVKUmVWZGc1amdxMUxac0ZWUnNiQkRIMUFZSEhZZGhDX0EzelU3aUdhZm12cjFlOWVLaTNvR2tjOHk1aDlnYl9CaTZudUpfNm50aXRMNThPa3RHVWdPQVk1S0E4VUFIWnM3MFctQk1xcUpHNVhuSzBVczYyQWdWUFQ3RG55TUV5Ny1xb0ZadUszQzJBLWFDTFhmRFM1UQ?oc=5","date":"2024-10-22","type":"regulatory","source":"BioPharma APAC","summary":"Thermo Fisher’s Oncomine Dx Target Test Receives FDA Approval to Guide Treatment with Servier’s VORANIGO® for Grade 2 IDH-Mutant Glioma - BioPharma APAC","headline":"Thermo Fisher’s Oncomine Dx Target Test Receives FDA Approval to Guide Treatment with Servier’s VORANIGO® for Grade 2 ID","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBvWURlbUxfQWxIYV9iSVNQMDJqQ3A3cHhWbkMzaUdPUndmNWRKbl9EV2VDaGpkTlVuamt3dWNBMXZFdkZMNXpLXzhaYmxoOUhIMUN1M1RVbzBNZjludE1OcUJfT2VwVVF1QVE?oc=5","date":"2023-06-24","type":"regulatory","source":"Wiley Online Library","summary":"Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study - Wiley Online Library","headline":"Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQdzExQjJZbzdQWnc2ZGlvUHJFRVo0cGQyWTBJLW1WdFJlLXJSOFFWWmNHWnczeUFaS3VTdWV3N2NNX21oc21LWnA4RFNOLS04RllPYVdiU3BMczhfZ1VHdmQxT256Ulc5VTZ5MG5sWWZBQVVrZGYyZHNlc0FOd3c2Y2pVbGRDQWdnWGFtSkVyQlBGN21tZzZsMGtHcE5zdw?oc=5","date":"2021-04-01","type":"pipeline","source":"BioSpace","summary":"Servier Completes Acquisition of Agios Pharmaceuticals’ Oncology Business - BioSpace","headline":"Servier Completes Acquisition of Agios Pharmaceuticals’ Oncology Business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE0wZlZoWDFtNUVWVzl3SkxDMnpzS0xjRFBEVm01ZU9pRUlBUWs4aWQzdVVER2lveXdtb3gtc3VlaHZ4U2JKQ0hUVEhVd2JEX1ZOV0lsU0gyalRPQU1abzNReVNwRnptZnloTV9CVjB3?oc=5","date":"2018-06-07","type":"deal","source":"pharmaphorum","summary":"Servier expands global footprint post Shire deal - pharmaphorum","headline":"Servier expands global footprint post Shire deal","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}